Sylvie Grégoire

Sylvie Louise Grégoire is the founder of EIP Pharma, Inc., founded in 2010, serving as Executive Chairman.
Dr. Grégoire is the founder of CervoMed, Inc., founded in 1995, serving as Director.
Dr. Grégoire currently holds the position of Chairman at Abivax SA since 2024.
Dr. Grégoire is Director at F2G Ltd. since 2021.
Dr. Grégoire is a Member of the Supervisory Board at Shire Orphan Therapies GmbH.
Former positions include President, CEO & Executive Director at GlycoFi, Inc. (2004–2005); Chairman at MetrioPharm AG; Executive Chairman at Takeda Pharmaceutical Co., Ltd. (2006–2007); Chairman at Corvidia Therapeutics, Inc. (2016–2020); Independent Director at Cubist Pharmaceuticals LLC (2006–2011); Director at Thallion Pharmaceuticals, Inc.; Director at CellCarta Biosciences, Inc.; Director at Vifor Pharma Management AG; Director at Novo Nordisk Ltd.; Director at Galenica AG; Director at Revvity, Inc.; Non-Executive Director at Corden Pharma Fribourg SA (2013–2019); Director at IDM Pharma, Inc. (2005–2008); Independent Director at Revvity, Inc. (2015–2024); Independent Director at Novo Nordisk A (2015–2025); Executive Vice President-Technical Operations at Biogen MA, Inc. (2001–2003); Executive Vice President-Business Development at Biogen, Inc. (2001–2003); President at Shire Human Genetic Therapies, Inc. (2007–2013); President-Human Genetic Therapies Division at Shire Plc (2007–2013).
Education includes a doctorate from State University of New York at Buffalo (1986), an undergraduate degree from Université Laval (1984), and an undergraduate degree from Séminaire de Sherbrooke (1980).